Subscribe

Categories

Add to Technorati Favorites

 Subscribe in a reader

Trends and Outliers

TIBCO Spotfire's Business Intelligence Blog

Category Archives: Life Sciences and Pharmaceuticals

07/22
2013

Winning in Pharmaceutical Emerging Markets with Analytics

Over the next five years, two-thirds of pharmaceutical sales growth will come from emerging markets. While this presents enormous potential, how can organizations compete to capture new opportunities? It all comes down to the data..

This infographic lays it all out.  Click anywhere on the image for a larger view.

Tibco Spotfire v 5b.fw  e1374503655153 Winning in Pharmaceutical Emerging Markets with Analytics

 

Print post

06/19
2013

Spotfire’s Michael O’Connell: Why Data Visualization Matters

Michael O’Connell, Spotfire’s chief data scientist, really digs data visualization. So much so that he wrote a book about it. Since this is a hot topic in data analytics today, we want to give you a look inside the value of data visualization from O’Connell’s point of view.

michale Spotfires Michael OConnell: Why Data Visualization Matters 1. Why do you think visuals explain data better? What is the business benefit? 

O’Connell: Graphics force people across the business to see what they never expected to see. Information visuals, combined with descriptive and predictive analytics, highlight the unknown unknowns in data in a way that can radically affect business practices.

See how O’Connell defines big data in this short video clip. Takeaway: visualization helps harness data that “is difficult to analyze in memory.”

Continue reading »

Print post

04/08
2013

Data Analysis to Boost Drug Development for Pharma Companies

col pharma biotech strategic services business development launch analogs benchmarking ci licencing 350 150x150 Data Analysis to Boost Drug Development for Pharma CompaniesThe recent Spotfire on-demand webcast, “Data Science 2.0: Guided and In-line Analytics with Spotfire,” covers how Spotfire and data science are impacting global business across every market and industry.

For example, if you work in the pharmaceuticals industry this may mean using analytics in clinical trials to identify safety issues more quickly and bring effective therapies to market faster.

 

 

Here’s a sample clip from the pharmaceuticals segment of the webcast:

 Data Analysis to Boost Drug Development for Pharma Companies

Perhaps no sector of the economy could benefit more from big data and the use of predictive analytics to churn through vast expanses of information than the pharmaceutical industry.

Continue reading »

Print post

08/07
2012

Business Data Visualization: How to Bring 27 Million Data Points to Life

When it comes to relying  on real-time BI and business data visualization to power decisions, life sciences companies are no different than companies in other industries.

life sciences1 150x150 Business Data Visualization: How to Bring 27 Million Data Points to LifeGold in the Data; But Where to Start?

Big data points exist in the millions for companies in this growing industry. And the need to aggregate and visualize all of that structured and unstructured data is crucial to life science companies looking to derive value from this previously untapped data.

“Finding new insights through data discovery across enterprise transaction data and unstructured data such as social media activity, email, call center records and incorporating them into analytics processes will unlock new ways to personalize customer experiences and to drive innovation, growth and productivity,” says Rita Sallam, an analyst at Gartner Inc.

Continue reading »

Print post

03/26
2012

Using Analytics to Stay on Top of the Regulatory Landscape

global analytics4 150x150 Using Analytics to Stay on Top of the Regulatory LandscapeRegulatory, data protection, and privacy requirements are constantly changing across different countries and regions, making it extremely challenging for finance, operations, and risk management executives to stay abreast of the ever-changing regulatory environment.

Many companies struggle to keep pace with local changes to consumer rights, cross-border data transfer restrictions, tax obligations, and a raft of additional regulatory requirements.

This includes the onus on Fortune 500 multinationals to keep up with the constant changes that are occurring in the regulatory environment on a global basis.

The challenges to keep up with regulatory modifications have become more acute following the global financial crisis that started in 2007. As Deloitte notes in a report on the topic, the aftermath of the crisis has resulted in extensive regulatory reform – not just in the US but in countries around the world. The Deloitte report focuses on steps that regulators can take to use analytics to collect, aggregate, analyze and share information about the health of the financial system and its participants.

Decision makers for financial services companies can use visual analytics tools to help identify and act on real-time changes in the global regulatory landscape so they can continue moving forward with business strategies instead of staying mired in prolonged market analysis.

This kind of paralysis-by-analysis is not only for valid financial services companies but for any type of organization that operates in a highly-regulated industry. Business leaders need tools that can help them make quick and precise decisions. They don’t have time to get bogged down in the regulatory quagmire.

Still, the nature and scale of these regulatory shifts shouldn’t be taken lightly. This is especially true for business leaders who have active roles in research or product development/product rollout where regulatory or compliance requirements in a particular geography can suddenly derail ambitious marketing plans.

For example, biotechnology and pharmaceutical professionals who are concerned with regulatory updates within their areas of focus are increasingly using web analytics and other types of discovery tools to stay abreast of the latest policies and enforcements that may affect their areas of research or product development.

It’s imperative that they keep up to speed with the ever-changing regulatory climate. A May 2011 study found that US regulatory approvals for biologic drugs and biotechnology products made from human or animal proteins have nearly doubled over the past decade.

Intuitive and visual analytics tools can make the job of tracking the evolving regulatory landscape much easier and more effective.

Next Steps: To learn more about this topic, check out our 5-Minute Guide to Analytics for Financial Planning & Analysis.

 

 

Print post

02/07
2012

Is Life Sciences the New Frontier for Analytics?

pharmaceuticals mfg 150x150 Is Life Sciences the New Frontier for Analytics?Researchers say pharmaceutical and other life sciences companies are ramping up their uses of analytics tools to help identify and take advantage of new market opportunities. This includes the use of analytics to identify gaps in treatment options as well as the need for specific types of drugs and therapeutic treatments.

Regulatory changes and other seismic industry shifts are helping to fuel interest in analytics tools. Blockbuster pharmaceutical developments such as Lipitor, the cholesterol-reducing treatment sold by Pfizer, and Plavix, used to treat atherosclerosis and sold by Bristol-Myers Squibb Sanofi, have generated billions of dollars in revenues for life sciences companies. Still, such discoveries and commercial successes are few and far between.

Continue reading »

Print post

10/25
2010

How Data Analytics Will Solve Our Biggest Problems

j04075531 150x150 How Data Analytics Will Solve Our Biggest ProblemsResearchers are close to testing a vaccine for HIV that was developed based on data analytics. A hospital was able to predict which patients recovering from congestive heart failure might be readmitted, monitor them (a $500 cost), and prevent another hospital stay (a $15,000 cost). Another healthcare provider discovered $10 Million in underpayments within the first six months of using data analytical tools. From saving money to saving lives, the next scientific revolution will occur through data analytics, according to “The Big Idea” feature in the November Harvard Business Review.

Continue reading »

Print post

07/12
2010

Free Webcast: Clinical Trial Operations with Spotfire Clinical Software at Infinity Pharmaceuticals

8880 Free Webcast: Clinical Trial Operations with Spotfire Clinical Software at Infinity PharmaceuticalsJoin John Walker of Infinity Pharmaceuticals and TIBCO Spotfire’s Michael O’Connell tomorrow for a case study discussion of clinical trial operations and medical/safety analysis with Spotfire at Infinity.

Date: Tuesday, July 13th, 2010 @ 11:00 AM ET

Overview: Infinity’s integrated clinical systems, consisting of custom CTMS (iTrac), Pharmacovigilance (Oracle ARGUS), EDC (Medidata) and a CDISC-compliant data warehouse (CRICIT) enables the timely analysis of clinical data to meet strategic and tactical needs. The platform’s automated reporting and a progressive approach to data visualization and analysis has led to broad use throughout the company.

TIBCO Spotfire Clinical software serves as a primary mechanism for data review, transforming all aspects of clinical operations and medical review. The recent release of Clinical Operations and Safety dashboards have leveraged all of these components and have allowed the relevant teams to generate higher quality decisions with greater efficiency and productivity.

Print post

05/13
2010

Can Analytics Change Meetings?

j0442889 150x150 Can Analytics Change Meetings?A new report by CITO argues that analytics can change the way meetings are conducted.  That analytics can change “the vicious cycle of meetings.”  This cycle is defined as meetings were “questions are asked beforehand, data collected, reports generated, and in due course, slides and spreadsheets publicly presented.”  When an unanticipated question is asked, the response is often “we’ll get back to you.”  And that creates a need for another meeting.

Continue reading »

Print post

11/18
2009

Clinical Data Analysis Delivers for Pharmaceutical Companies

j03210561 150x150 Clinical Data Analysis Delivers for Pharmaceutical CompaniesPharmaceutical companies rely on clinical data analysis to make better business decisions in the drug delivery market.  Using clinical data analysis, pharma companies can identify potential issues earlier in the drug development process, ultimately saving the company development costs.

Continue reading »

Print post